The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Safety and pharmacodynamics of dalazatide, a Kv1.3 channel inhibitor, in the treatment of plaque psoriasis: A randomized phase 1b trial
Open accessAbstract
BACKGROUND: Dalazatide is a specific inhibitor of the Kv1.3 potassium channel. The expression and function of Kv1.3 channels are required for the function of chronically activated memory T cells, which have been shown to be key mediators of autoimmune diseases, including psoriasis. OBJECTIVE: The primary objective was to evaluate the safety of repeat doses of dalazatide in adult patients with mild-to-moderate plaque psoriasis. Secondary objectives were to evaluate clinical proof of concept and the effects of dalazatide on mediators of inflammation in the blood and on chronically activated memory T cell populations. METHODS: Patients (n = 24) were randomized 5:5:2 to receive dalazatide at 30 mcg/dose, 60 mcg/dose, or placebo twice weekly by subcutaneous injection (9 doses total). Safety was assessed on the basis of physical and neurological examination and laboratory testing. Clinical assessments included body-surface area affected, Psoriasis Area and Severity Index (PASI), and investigator and patient questionnaires. RESULTS: The most common adverse events were temporary mild (Grade 1) hypoesthesia (n = 20; 75% placebo, 85% dalazatide) and paresthesia (n = 15; 25% placebo, 70% dalazatide) involving the hands, feet, or perioral area. Nine of 10 patients in the 60 mcg/dose group had a reduction in their PASI score between baseline and Day 32, and the mean reduction in PASI score was significant in this group (P < 0.01). Dalazatide treatment reduced the plasma levels of multiple inflammation markers and reduced the expression of T cell activation markers on peripheral blood memory T cells. LIMITATIONS: The study was small and drug treatment was for a short duration (4 weeks). CONCLUSION: This study indicates that dalazatide is generally well tolerated and can improve psoriatic skin lesions by modulating T cell surface and activation marker expression and inhibiting mediators of inflammation in the blood. Larger studies of longer duration are warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the only class of Kv1.3 channel blockers that has successfully completed phase Ib studies in humans for psoriasis (ShK analogs) has not been tested in pre-clinical models of AD pathology [53, 54].”
From Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer’s disease (2018) · cites this paper as [53]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“ShK-223 was selected due to its improved stability and > 10,000-fold selectivity for Kv1.3 channels over neuronal Kv channels [53, 54].”
From Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer’s disease (2018) · cites this paper as [53]
Experimental — accuracy not yet measuredIn the citing paper
“Our pre-clinical findings using ShK-223 are of translational importance because a Kv1.3-blocking ShK analog (dalazatide or ShK-186) that is very similar to ShK-223, is the only selective Kv1.3 blocker to have successfully completed early phase human studies for systemic autoimmunity [53].”
From Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer’s disease (2018) · cites this paper as [53]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Schweiger, D., Baufeld, C., Drescher, P., Oltrogge, B., Höpfner, S., Mess, A., Lüttke, J., Rippke, F., Filbry, A., & Max, H. (2013) · Skin Pharmacology and Physiology · doi:10.1159/000348473 · Cited by 1,346
Arican, O., Aral, M., Sasmaz, S., & Ciragil, P. (2005) · Mediators of Inflammation · doi:10.1155/mi.2005.273 · Cited by 805
Psoriasis prevalence among adults in the United States
Rachakonda, T. D., Schupp, C. W., & Armstrong, A. W. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.11.013 · Cited by 783
CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris
Abrams, J. R., Lebwohl, M. G., Guzzo, C. A., Jegasothy, B. V., Goldfarb, M. T., Goffe, B. S., Menter, A., Lowe, N. J., Krueger, G., Brown, M. J., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5857 · Cited by 597
Treatment of Chronic Plaque Psoriasis by Selective Targeting of Memory Effector T Lymphocytes
Ellis, C. N., & Krueger, G. G. (2001) · New England Journal of Medicine · doi:10.1056/nejm200107263450403 · Cited by 582
Guidelines of care for the management of psoriasis and psoriatic arthritis
Menter, A., Korman, N. J., Elmets, C. A., Feldman, S. R., Gelfand, J. M., Gordon, K. B., Gottlieb, A. B., Koo, J. Y. M., Lebwohl, M., Lim, H. W., et al. (2009) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2009.03.027 · Cited by 558
Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases
Beeton, C., Wulff, H., Standifer, N. E., Azam, P., Mullen, K. M., Pennington, M. W., Kolski-Andreaco, A., Wei, E., Grino, A., Counts, D. R., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605136103 · Cited by 538
The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses
Lowes, M. A., Russell, C. B., Martin, D. A., Towne, J. E., & Krueger, J. G. (2013) · Trends in Immunology · doi:10.1016/j.it.2012.11.005 · Cited by 537
Resident memory T cells in human health and disease
Clark, R. A. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.3010641 · Cited by 446
The voltage-gated Kv1.3 K+ channel in effector memory T cells as new target for MS
Wulff, H., Calabresi, P. A., Allie, R., Yun, S., Pennington, M., Beeton, C., & Chandy, K. G. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16921 · Cited by 422
Cited by
Rangaraju, S., Dammer, E. B., Raza, S. A., Rathakrishnan, P., Xiao, H., Gao, T., Duong, D. M., Pennington, M. W., Lah, J. J., Seyfried, N. T., et al. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0254-8 · Cited by 430
“3 channels over neuronal Kv channels [53, 54].”
BackgroundSchendel, V., Rash, L. D., Jenner, R. A., & Undheim, E. A. B. (2019) · Toxins · doi:10.3390/toxins11110666 · Cited by 285
“Consequently, toxins have been an important source of molecular tools for dissecting physiological processes [3], and lead molecules for the development of drugs targeting a range of conditions such as chronic pain [4], diabetes [5], cancer [6], stroke [7], and autoimmune disease [8].”
Peptide therapeutics from venom: Current status and potential
Pennington, M. W., Czerwinski, A., & Norton, R. S. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.09.029 · Cited by 278
Antibodies and venom peptides: new modalities for ion channels
Wulff, H., Christophersen, P., Colussi, P., Chandy, K. G., & Yarov-Yarovoy, V. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0013-8 · Cited by 182
Animal toxins — Nature’s evolutionary-refined toolkit for basic research and drug discovery
Herzig, V., Cristofori-Armstrong, B., Israel, M. R., Nixon, S. A., Vetter, I., & King, G. F. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114096 · Cited by 181
Metadata
- Authors
- Tarcha, E. J., Olsen, C. M., Probst, P., Peckham, D., Muñoz-Elías, E. J., Kruger, J. G., & Iadonato, S. P.
- Affiliations
- Kineta (United States) (US)
- Rockefeller University (US)
- Corresponding author
- Olsen, Chelsea M.
- ORCID
- Olsen, Chelsea M.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2017-07-19
- Volume
- 12
- Issue
- 7
- Pages
- e0180762
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC5516987
- OpenAlex
- W2737389332
- Cited by
- 167
- References
- 48
- Citations by year
- 2026: 13 · 2025: 16 · 2024: 25 · 2023: 14 · 2022: 22 · 2021: 20 · 2020: 18 · 2019: 20 · 2018: 13 · 2017: 6
- FWCI
- 7.18
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ion channel regulation and function
- Keywords
- plaque psoriasis, memory T cells, drug safety, pharmacodynamics, numbness, paresthesia, inflammatory markers, T cell activation markers, PASI, subcutaneous injection
- MeSH terms
- Adult, Double-Blind Method, Female, Humans, Hypesthesia, Male, Middle Aged, Paresthesia, Proteins, Psoriasis, Treatment Outcome, Potassium Channel Blockers, Kv1.3 Potassium Channel
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.